Oncology Venture reports from Biotech JPMorgan in US
Oncology Venture (OV) participated at the Biotech Showcase 11-13 January 2016 which takes place in relation to the JPMorgan Healthcare Conference and every year attracts decision makers from Big Pharma, Biotech and Investors as well as other important players in the field to meet and kick off the new year in the pharma society. This year more than twenty thousand people met in San Francisco, US.
The overall hot topic was Immuno-Oncology as a consequence of the recent fantastic successes with immune-therapy for cancer patients– a sweet spot for OV’s APO010 (please see later).
Oncology Venture had a very full calendar with more than 50 meetings including ongoing partner discussions and also new contacts set up as face to face meetings at the Biotech Showcase event.
Meetings took place with drug owners who possess drugs of high interest to OV - where OV has a good Drug Response Predictor - and where we believe we can change the odds considerably for the product under development.
Meetings also took place with pharma and biotech interested in our current portfolio of drugs: Irofulven – developed from a natural fungus (for prostate cancer) and APO010 – an Immuno-Oncology product that works as a small focused T-Cell with the same killing mechanism of the cancer as the natural immune system. Immuno-Oncology is a hot topic and a whole workshop was dedicated Immuno-Oncology and called ‘Investing in the immune-oncology revolution: Follow the T-Cell’. OV aims to use APO010 in patients with Breast Cancer and Multiple Myeloma (a type of blood cancer). T-Cells are not often abundant in breast cancer and therefore immune-oncology in this disease could benefit from APO010.
APO010 could be a relevant combination with products like PD-1 and PDL-1 blockers that regulate the effect of the T-Cells.
Finally, but equally important the team had meetings with potential new investors where we also had a very positive feedback on our business model where we use the DRP® technology to change a product ‘from Zero to Hero’.
Peter Buhl Jensen, CEO of Oncology Venture says: “We had a very positive conference and gained much positive interest for Oncology Venture as a business case and new approach to Drug Response Prediction. In our drug portfolio APO010 – Oncology Ventures Immuno-oncology product for Multiple Myeloma received a lot of attention. There were several highly interesting drugs for our future portfolio and I look very much forward to follow up on exiting opportunities from the meeting.
For more information, please contact:
Peter Buhl Jensen, CEO
Phone: +45 21 60 89 22
E-mail: pbj@buhloncology.com
About Oncology Venture Sweden AB
Oncology Venture improves the odds compared to traditional drug development. Instead of treating all patents with the same cancer disease patients will be screened beforehand and only patients who have a likelihood of responding to the anti-cancer drug will then be treated. Having a better defined patient population risk, cost will be reduced, and the development process will be more efficient and the cancer product and OV’s Companion Diagnostic can lead to clinical and commercial success. OV aims to sell the combined solution after proof-of-concept.
Our current portfolio of drugs: Irofulven – developed from a natural fungus (for prostate cancer where it worked in 10% of unselected patients) and APO010 – a T-Cell mimic Immuno-Oncology product (for Multiple Myeloma – a blood cancer and Breast cancer).
Oncology Venture has license to use Drug Response Prediction – DRPTM – to significantly increase the likelihood of success in clinical trials. Oncology Venture aims to rescue cancer drugs, which has shown excellent anticancer activity but in too few of the treated patients to obtain approval. DRPTM has demonstrated statistically significant prediction of clinical trial results in 26 out of 32 tested clinical studies.
Oncology Venture Sweden AB runs cancer drug development through the fully owned Danish daughter company Oncology Venture ApS.